Literature DB >> 6124804

Phenotype study of apolipoprotein E isoforms in hyperlipoproteinaemic patients.

G Ghiselli, R E Gregg, L A Zech, E J Schaefer, H B Brewer.   

Abstract

It has been suggested that apolipoprotein E (apoE) is inherited at a single genetic locus with three common alleles designated E2, E3, and E4. The products of these three alleles are apoE2, apoE3, and apoE4. The apoE phenotypes of 74 normal subjects and 226 hyperlipoproteinaemic subjects were ascertained by gel isoelectrofocusing. Patients with type I, type IIa, type IIb, and type IV hyperlipoproteinaemia had an apoE phenotypic distribution which was similar to that of normal subjects, with 40.0 to 60.0% being homozygous for E3. In contrast, 75% of type III patients had an E2 phenotype and 25% were E2/3 heterozygotes. Among type V patients 31.4% had an E4 phenotype, and 42.9% were E4 heterozygotes. No type III patient and only 5.7% of type V patients had E3 phenotype. The results suggest that apoE2 and apoE4 are associated with two distinctly different dyslipoproteinaemias and that apoE has at least two different physiological functions.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124804     DOI: 10.1016/s0140-6736(82)90439-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  Apolipoprotein E phenotypes and hyperlipidemia.

Authors:  G Utermann; I Kindermann; H Kaffarnik; A Steinmetz
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

2.  Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.

Authors:  M R Wardell; S O Brennan; E D Janus; R Fraser; R W Carrell
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

3.  Green fluorescent protein-tagged apolipoprotein E: A useful marker for the study of hepatic lipoprotein egress.

Authors:  Constantin N Takacs; Ursula Andreo; Rachel L Belote; Joan Pulupa; Margaret A Scull; Caroline E Gleason; Charles M Rice; Sanford M Simon
Journal:  Traffic       Date:  2017-01-31       Impact factor: 6.215

4.  Effect of 25-hydroxycholesterol and bile acids on the regulation of cholesterol metabolism in Hep G2 cells.

Authors:  T L Carlson; B A Kottke
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

5.  Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation.

Authors:  C F Sing; J Davignon
Journal:  Am J Hum Genet       Date:  1985-03       Impact factor: 11.025

6.  Modification by acrolein, a component of tobacco smoke and age-related oxidative stress, mediates functional impairment of human apolipoprotein E.

Authors:  Shiori Tamamizu-Kato; Jason Yiu Wong; Vikram Jairam; Koji Uchida; Vincent Raussens; Hiroyuki Kato; Jean-Marie Ruysschaert; Vasanthy Narayanaswami
Journal:  Biochemistry       Date:  2007-06-20       Impact factor: 3.162

7.  Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype.

Authors:  S C Rall; K H Weisgraber; T L Innerarity; T P Bersot; R W Mahley; C B Blum
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

8.  The isolation of cDNA clones for human apolipoprotein E and the detection of apoE RNA in hepatic and extra-hepatic tissues.

Authors:  S C Wallis; S Rogne; L Gill; A Markham; M Edge; D Woods; R Williamson; S Humphries
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

9.  Association between a variation in the phosphodiesterase 4D gene and bone mineral density.

Authors:  Richard H Reneland; Steven Mah; Stefan Kammerer; Carolyn R Hoyal; George Marnellos; Scott G Wilson; Philip N Sambrook; Tim D Spector; Matthew R Nelson; Andreas Braun
Journal:  BMC Med Genet       Date:  2005-03-07       Impact factor: 2.103

10.  Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).

Authors:  Elisa Waldmann; Liya Wu; Kristina Busygina; Julia Altenhofer; Kerstin Henze; Alexander Folwaczny; Klaus G Parhofer
Journal:  PLoS One       Date:  2022-03-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.